InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | 2026-05-13 | Binder Steven B. | Director | Sale | 16.9K | $3.29 | $56K | 808.0K | View ↗ | |
| 2026-05-12 | 2026-05-13 | Thomson David | EVP Genl Counsel & Secretary | Sale | 3,033 | $3.29 | $10K | 826.3K | View ↗ | |
| 2026-03-10 | 2026-03-10 | Castagna Michael | Director & Chief Executive Officer | Purchase | 100.0K | $2.59 | $259K | 2.58M | View ↗ | |
| 2025-12-02 | 2025-12-04 | Thomson David | EVP Genl Counsel & Secretary | Sale | 147.8K | $5.57 | $823K | 841.7K | View ↗ | |
| 2025-07-16 | 2025-07-17 | Thomson David | EVP Genl Counsel & Secretary | Sale | 7,466 | $3.94 | $29K | 841.7K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $128.1M+25.2% | $102.3M+42.2% | $72.0M+361.4% | $15.6M-79.3% | $75.4M |
| Cost of goods sold - commercial, excluding amortization of acquired intangible assets | $26.8M+53.8% | $17.4M-16.5% | $20.9M+30.4% | $16.0M-4.9% | $16.8M |
| Research and development | $66.3M+44.6% | $45.9M+46.7% | $31.3M+58.6% | $19.7M+60.2% | $12.3M |
| Selling, general and administrative | $144.1M+52.8% | $94.3M+0.0% | $94.3M+3.1% | $91.5M | — |
| Amortization of acquired intangible assets | $4.0M | — | — | — | — |
| Loss (gain) on foreign currency transaction | $7.7M+298.3% | -$3.9M-303.9% | $1.9M+139.8% | -$4.8M+26.7% | -$6.6M |
| Total expenses | $310.2M+45.7% | $212.9M+11.9% | $190.3M+16.1% | $163.9M+33.8% | $122.5M |
| Income from operations | $38.8M-46.5% | $72.6M+736.4% | $8.7M+113.5% | -$64.1M-36.3% | -$47.0M |
| Interest income, net | $8.1M-36.2% | $12.6M+105.0% | $6.2M+144.9% | $2.5M+2143.8% | $112K |
| Interest expense on liability for sale of future royalties | -$14.4M+10.7% | -$16.2M-8641.6% | -$185K | — | — |
| Interest expense | -$13.8M-15.4% | -$12.0M+20.9% | -$15.2M-0.9% | -$15.0M+1.3% | -$15.2M |
| Interest expense on financing liability | -$9.8M+0.8% | -$9.8M-0.0% | -$9.8M-0.7% | -$9.8M-610.7% | -$1.4M |
| Impairment of available-for-sale investment | -$6.4M-313.5% | -$1.6M-811.8% | -$170K | — | — |
| Gain on bargain purchase | $5.3M | — | — | — | — |
| Other (expense) income | -$1.0M-3253.1% | $32K-73.8% | $122K+219.6% | -$102K+57.3% | -$239K |
| Loss on settlement of debt | -$20.4M | — | — | — | — |
| Total other expense | -$37.4M+11.1% | -$42.1M-120.8% | -$19.1M+18.2% | -$23.3M+31.3% | -$33.9M |
| Income before income tax (benefit) expense | $1.4M-95.4% | $30.5M+394.1% | -$10.4M+88.1% | -$87.4M-8.0% | -$80.9M |
| Income tax (benefit) expense | -$4.5M-252.1% | $2.9M+87.7% | $1.6M | — | — |
| Net Income (Loss) | $5.9M-78.7% | $27.6M+331.1% | -$11.9M+86.3% | -$87.4M-8.0% | -$80.9M |
| Net income (loss) per share - basic | $20-80.0% | $100+350.0% | -$40+88.2% | -$340-6.3% | -$320 |
| Weighted average shares used to compute net income (loss) per share - basic | $305.6M+11.4% | $274.4M+2.8% | $267.0M+3.9% | $257.1M+3.1% | $249.2M |
| Net income (loss) per share - diluted | $20-80.0% | $100+350.0% | -$40+88.2% | -$340-6.3% | -$320 |
| Weighted average shares used to compute net income (loss) per share - diluted | $314.1M+10.7% | $283.8M+6.3% | $267.0M+3.9% | $257.1M+3.1% | $249.2M |
| Commercial product sales | |||||
| Collaborations and services | |||||
| Cost of revenue - collaborations and services | $61.2M+3.4% | $59.2M+41.2% | $41.9M+1.0% | $41.5M+88.4% | $22.0M |
| Royalties | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
MannKind to Present at Jefferies Global Healthcare Conference
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M